SRR8752369
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.570
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.540
- HEDGEHOG_SIGNALING+0.470
- TGF_BETA_SIGNALING+0.460
- UV_RESPONSE_DN+0.370
- APICAL_JUNCTION+0.350
- WNT_BETA_CATENIN_SIGNALING+0.260
- ANGIOGENESIS+0.250
- ESTROGEN_RESPONSE_EARLY+0.250
- TNFA_SIGNALING_VIA_NFKB+0.240
Top 10 suppressed
- MYC_TARGETS_V1-0.360
- XENOBIOTIC_METABOLISM-0.310
- DNA_REPAIR-0.300
- PROTEIN_SECRETION-0.300
- E2F_TARGETS-0.270
- G2M_CHECKPOINT-0.270
- MYC_TARGETS_V2-0.270
- UNFOLDED_PROTEIN_RESPONSE-0.250
- INTERFERON_ALPHA_RESPONSE-0.230
- MTORC1_SIGNALING-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | DRR168525 | — | — | 0.841 |
| 2 | 20050037.TNBC | — | C | 0.823 |
| 3 | SRR35579834 | — | A | 0.814 |
| 4 | TCGA-A2-A3KC-01A-11R-A213-07 | — | A | 0.813 |
| 5 | f65f4ed5-9726-4eff-8638-63752686d2c9 | — | — | 0.813 |
| 6 | TCGA-SY-A9G0-01A-12R-A38B-07 | — | — | 0.810 |
| 7 | MNG128 | — | — | 0.808 |
| 8 | TCGA-EW-A1IX-01A-12R-A144-07 | — | A | 0.804 |
| 9 | TCGA-OL-A6VQ-01A-12R-A41B-07 | — | A | 0.799 |
| 10 | TCGA-E2-A1IO-01A-11R-A144-07 | — | A | 0.798 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.570 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.540 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.470 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.460 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.370 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.350 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.260 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.250 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.250 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.240 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.220 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.210 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.180 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.180 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.160 | Temsirolimus | — uncovered |
| MITOTIC_SPINDLE | 0.160 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.160 | Cobimetinib | — uncovered |
| UV_RESPONSE_UP | 0.140 | Idelalisib | — uncovered |
| APOPTOSIS | 0.130 | Idelalisib | — uncovered |
| HYPOXIA | 0.120 | Idelalisib | — uncovered |